Becton, Dickinson and Company Life Sciences — Selling and administrative expense increased by 725.2% to $1.21B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.6%, from $1.12B to $1.21B. This increase may warrant attention — for this metric, lower values are generally preferred.
Rising expenses may indicate aggressive market expansion or increased administrative overhead, while declining expenses may suggest cost-cutting or operational streamlining.
This includes the costs of sales, marketing, and general administrative functions specifically allocated to the Life Sci...
Standard SG&A expense reporting for business segments in large-cap healthcare companies.
bdx_segment_life_sciences_selling_and_administrative_expense| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.20B | $1.22B | $1.19B | $1.19B | $1.15B | $1.18B | $1.19B | $170.00M | $1.21B | $170.00M | $1.19B | $170.00M | $1.14B | $170.00M | $1.21B | $175.50M | $1.19B | $175.50M | $1.20B | $175.50M | $1.26B | $175.50M | $1.32B | $142.00M | $1.12B | $1.32B | $1.52B | $1.39B | $147.00M | $1.21B |
| QoQ Change | — | +1.8% | -3.0% | +0.6% | -3.6% | +3.0% | +0.3% | -85.7% | +608.8% | -85.9% | +600.0% | -85.7% | +568.8% | -85.0% | +613.5% | -85.5% | +579.8% | -85.3% | +581.5% | -85.3% | +615.1% | -86.0% | +651.0% | -89.2% | +686.6% | +18.2% | +15.4% | -8.5% | -89.4% | +725.2% |
| YoY Change | — | — | — | — | -4.3% | -3.2% | +0.2% | -85.7% | +1.1% | -85.7% | +3.6% | -85.2% | -3.9% | -85.6% | +2.2% | -85.2% | -1.0% | -85.4% | +0.5% | -85.3% | +10.4% | -84.6% | +8.7% | -88.3% | -6.4% | +10.4% | +21.4% | +5.7% | -88.8% | +8.6% |